APOBEC3B and breast cancer: Based on the results, the authors constructed a model suggesting that A3B-catalyzed deamination provides a continuous source of DNA damage for breast cancer cells, leading to selection for TP53 inactivation; this model explains why some tumors progress rapidly and exhibit heterogeneity (70).